Savara (SVRA) Free Cash Flow (2010 - 2026)
Savara (SVRA) reported Free Cash Flow of -$33.1 million for Q1 2026, down 21.56% year-over-year from -$42.1 million in Q1 2025, and down 31.9% quarter-over-quarter from -$25.1 million in Q4 2025.
Savara (SVRA) Free Cash Flow (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Free Cash Flow data on file, last reported at -$33.1 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$33.1 million, down 21.56% year-over-year; the trailing twelve-month figure through Mar 2026 was -$106.9 million (down 11.78% YoY), and the FY2025 annual result was -$101.1 million, down 13.41% from the prior year.
- Free Cash Flow retreated to -$33.1 million in Q1 2026 per SVRA's latest filing, from -$25.1 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$8.2 million in Q3 2022 and troughed at -$33.1 million in Q1 2026.
- A 5-year average of -$18.2 million and a median of -$20.7 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow increased 23.6% in 2022, then plunged 114.5% in 2024.
- A 5-year view of Free Cash Flow shows it stood at -$8.7 million in 2022, then sank by 80.64% to -$15.6 million in 2023, then slumped by 48.92% to -$23.3 million in 2024, then retreated by 7.68% to -$25.1 million in 2025, then slumped by 31.9% to -$33.1 million in 2026.
- Business Quant data shows SVRA's Free Cash Flow at -$33.1 million in Q1 2026, -$25.1 million in Q4 2025, and -$22.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | -33.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.05 Mn |
| Mar 31, 2026 | -33.05 Mn |
| Dec 31, 2025 | -25.06 Mn |
| Dec 31, 2025 | -25.06 Mn |
| Sep 30, 2025 | -22.53 Mn |
| Sep 30, 2025 | -22.53 Mn |
| Jun 30, 2025 | -26.28 Mn |
| Jun 30, 2025 | -26.28 Mn |
| Mar 31, 2025 | -27.19 Mn |
| Mar 31, 2025 | -27.19 Mn |
| Dec 31, 2024 | -23.27 Mn |
| Dec 31, 2024 | -23.27 Mn |
| Sep 30, 2024 | -22.67 Mn |
| Sep 30, 2024 | -22.67 Mn |
| Jun 30, 2024 | -22.52 Mn |
| Jun 30, 2024 | -22.52 Mn |
| Mar 31, 2024 | -20.65 Mn |
| Mar 31, 2024 | -20.65 Mn |
| Dec 31, 2023 | -15.63 Mn |
| Dec 31, 2023 | -15.63 Mn |